Eli Lilly's stock declined 1.0% despite several positive developments. Novo Nordisk's experimental obesity drug CagriSema failed to meet its primary endpoint in a head-to-head trial, showing 23% weight loss compared to Eli Lilly's tirzepatide at 25.5% weight loss. This trial setback caused Novo Nordisk shares to fall over 15%. Eli Lilly announced FDA approval for a multi-dose pen version of its Zepbound obesity drug, offering a month's supply in a single device at prices starting at $299. The company also reported positive Phase 3b trial results showing Taltz and Zepbound combination therapy achieved complete skin clearance in 27.1% of psoriasis patients with at least 10% weight loss. Additionally, Eli Lilly agreed to acquire Ventyx Biosciences for $14.00 per share in cash, with HSR clearance obtained.
Read full analysisEli Lilly's stock declined 1.0% despite several positive developments. Novo Nordisk's experimental obesity drug CagriSema failed to meet its primary endpoint in a head-to-head trial, showing 23% weight loss compared to Eli Lilly's tirzepatide at 25.5% weight loss. This trial setback caused Novo Nordisk shares to fall over 15%. Eli Lilly announced FDA approval for a multi-dose pen version of its Zepbound obesity drug, offering a month's supply in a single device at prices starting at $299. The company also reported positive Phase 3b trial results showing Taltz and Zepbound combination therapy achieved complete skin clearance in 27.1% of psoriasis patients with at least 10% weight loss. Additionally, Eli Lilly agreed to acquire Ventyx Biosciences for $14.00 per share in cash, with HSR clearance obtained.
Eli Lilly is one of the world's largest pharmaceutical companies, best known for its blockbuster diabetes drug Mounjaro and weight-loss treatment Zepbound — both GLP-1 receptor agonists that drove 43% revenue growth in Q4 2025 to $19.3 billion, with 2026 revenue guidance of $80-83 billion. The company is awaiting an FDA decision on its oral weight-loss pill orforglipron, expected in April 2026. Monday's confirmation that rival Novo Nordisk's next-generation CagriSema failed to match Zepbound's efficacy in a head-to-head trial reinforced Lilly's dominant position in the obesity drug market, and today's modest pullback follows that rally.